Biocompatibles Share Discussion Threads

[spyder] 21/9/2010 06:31

Wow - I didn't see that coming!!
It is a curious statement as it rather implies that the 'recent movement in the share price' is related to the offer, whereas, as naive as this might sound, I don't think there is any insider connection at all.
This might be a rash statement, but as has been observed above, the recent rise was triggered by a buy recommendation from DT's Questor (connected to the bid? Unlikely ...) and has been on the back of extremely thin volumes of just a few thousand shares a day.
Furthermore, this is an extremely well run company with a very high regard for corporate governance, social responsibility and fair treatment of all stakeholders.
I think the only likely connection between the rise and the bid is that it has flushed out a lurking predator who was waiting for an opportune moment to pounce and saw the price moving against them.
For what it is worth, I think any offer must start with a 5 ...

[adamapost] 20/9/2010 21:05

An Offer:



... The Board of Biocompatibles International plc (the "Company") notes the recent
movement in the Company's share price and can confirm that it has received a
preliminary approach, which may or may not lead to an offer being made for the
Company ...

Lets hope it is a good offer and if it is not then it is rejected. Institutions hold a lot of the shares. Lets see ....

[hieronymous1] 20/9/2010 17:56

Apad

I am 61 myself! Agree about DT readers - a few years ago the average age of their readers was over 65. They have attempted to modernise and appeal to the plebs.

For director share dealings try

Only covers the last two years unless perhaps you subscribe.

[apad] 20/9/2010 16:35

Hier...

It is Telegraph readers who are slow moving.
What's age got to do with it:-)

Buying BII is always problematic. Soddin' great spread and no volume. It's such a nice tech. punt that there is no point selling.

Hier...do you know of a decent website for current directors' holdings?
IC used to have them but have changed their system to recording director's trades.

[hieronymous1] 20/9/2010 15:44

Maybe it is just a very thin market. There are no large trades reported and 65% of the shares are held by the top three investors with another 9% held by the board, so a small free float. Also, Telegraph readers are quite elderly and slow moving so last week's recommendation may still be having an effect. :-)

[greek islander] 20/9/2010 14:48

DOUBLE POSTING!

[greek islander] 20/9/2010 14:48

Continuing the surge in the share price
Someone knows something we don't?

[fenners66] 17/9/2010 12:18

Very light volume... but all power to their elbow.. I'll wait and see if we can get to break even as well!

[gnnmartin] 17/9/2010 11:20

There was a detailed Edison note on BII on 9 Sept, which said "We indicate a long-term value of 520p with a further 120p of unrecognised value due to the GLP-1 diabetes product, CM3; this could yield €25m in 2011-12 from AstraZeneca."

I've held these shares for a long time. I had pretty much given up on them, but at this rate I might even get my money back! I did think that things were looking brighter. The chart certainly looks encouraging. The recent price rise has been on fairly light volume though.
Nigel Martin

[nellie1973] 16/9/2010 16:52

Tipped in press today as a buy

[gnnmartin] 16/9/2010 16:52

Is so, I've missed it too. :-O
Nigel Martin

[greek islander] 16/9/2010 16:49

Todays 10% rise a bit out of the blue or have I missed something?

[ceohunter] 10/9/2010 12:04

To view the presentation Biocompatibles gave at last night's Proactive Investors One2One Event, please click on the following link:

[ceohunter] 31/8/2010 09:38

The directors of Biocompatibles (LSE: BII), Silence Therapeutics (AIM: SLN), Renovo Group Plc (LSE: RNVO) and smartFOCUS Group (AIM: STF) will be presenting on Thursday the 9th September 2010 at the Chesterfield Mayfair Hotel, 35 Charles Street, Mayfair, W1J 5EB.

The presentations will start at 6:00pm and finish at approx 8:00pm. After the presentations are complete the directors will also be available to take questions during a free canapé and wine reception.

[tratante] 26/8/2010 13:02

Another excellent set of results. BII now profitable.

[hieronymous1] 23/6/2010 20:27

Does the RNS on Invesco holding nearly 24% have any significance? I cannot find a list of major sharejolders and the PDF of the last annual report is corrupt (at least that is the message I get).

[yespmedc] 23/6/2010 19:48

just noticed this recent document about BII on Stockopedia -

[andy] 15/5/2010 20:21

New article and updated analysis by Proactiveinvestors.com

[spyder] 13/5/2010 20:11

I am quite surprised this morning's very positive news didn't cause more of a stir, but I guess BII is just off the radar for too many people. However, it is an ill wind etc as this just creates a buying opportunity for those following the business.
I looks like BII has a winner in Novabel ...

From Beauty In The Bag

NOVABEL® FROM MERZ MAKES ITS EUROPEAN DEBUT!

By far the biggest buzz in the facial rejuvenation category is around the German pharmaceutical company Merz. In Europe, Merz Aesthetics includes a growing portfolio of fillers including Belotero, a hyaluronic acid derived product currently pursuing FDA approval in the US. However, the launch of the new Merz facial shaping agent called NOVABEL® has generated unprecedented excitement among practitioners. The immediate effects and minimal to no downtime make the case for NOVABEL® equally compelling for consumers in search of youthful contours and plumped up lines and folds.



"Merz's newest dermal filler, Novabel,
is in a class by itself, according to
Berthold Rzany, M.D., Sc.M., of the
Klinik für Dermatologie, Allergologie
und Venerologie, Charité - Universitätsmedizin
Berlin (Berlin, Germany). "This
is totally different from existing dermal
filler lines," he said. "Since it's not
a hyaluronic acid based filler there is
generally much less swelling, which
makes it easier to see results."

See here;


And here;

[tratante] 13/5/2010 13:26

Still on course!

* Revenue ahead of expectations

* Recruitment complete in first phase I trial of CM3

Revenue is ahead of Board expectations. Bead Products are performing strongly
and, within Licensing, there is good growth in sales of the Novabel®(1)
cosmetic dermal filler bead. In addition, Sterling weakness has contributed to
sales in both divisions.

The Company generated GBP2.2m of cash during the four months ended 30 April 2010, closing with cash of GBP35.2m (31 Dec 2009: GBP33.0m).

[graham142] 29/3/2010 16:32

What is happening with this stock....
I bought 4,000 shares before 10.00 o clock this morning and they are still not showing on any site that displays trades through the LSE as far as i know.
Up to 09.46 a total of 6750 shares had gone through the market resulting in a 1.92% increase in price. The actual total should have been at least 10,750 for today if you include my purchase.
Perhaps it has gone through on plus but i cannot get access to that...

[graham142] 29/3/2010 11:08

My 4k shares buy bought over an hour ago still not showing...

[raymund] 28/3/2010 21:29

Tratante,

Yes, I am well pleased with this company, think it will prove to be a solid and consistent performer. Have you seen the interview with the CEO, some imoressive medical science! About 20 minutes and well worth a listen